Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

Zhi-Yun Niu, Li Sun, Shu-Peng Wen, Zheng-Rong Song, Lina Xing, Ying Wang, Jian-Qiang Li, Xue-Jun Zhang, Fu-Xu Wang

ORCID number: Zhi-Yun Niu 0000-0002-8529-9341; Li Sun 0000-0002-4421-7207; Shu-Peng Wen 0000-0001-8377-6282; Zheng-Rong Song 0000-0001-8448-3545; Lina Xing 0000-0001-7746-5445; Ying Wang 0000-0002-4359-1758; Jian-Qiang Li 0000-0003-4410-0452; Xue-Jun Zhang 0000-0003-4984-862X; Fu-Xu Wang 0000-0002-3365-4428.

Author contributions: Wang FX conceptualized and designed the study; Niu ZY, Sun L and Wen SP performed the clinical trial; Xing LN, Li JQ, Song ZR and Wang Y acquired the data; Li JQ prepared the anti-CD19 CAR T-cells; Zhang XJ analyzed and interpreted the data; Niu ZY contributed to the writing and Wang FX revised the manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and

Abstract

BACKGROUND

Chimeric antigen receptor T cell (CART) therapy has benefited many refractory lymphoma patients, but some patients experience poor effects. Previous studies have shown that programmed cell death protein-1 (PD-1) inhibitors can improve and prolong the therapeutic effect of CAR-T cell treatment.

CASE SUMMARY

A 61-year-old male presented with 15-d history of diarrhea and lower-limb edema. A large mass was detected in the pelvis, and pathology indicated non-Hodgkin diffuse large B-cell lymphoma. After three cycles of the R-CHOP chemotherapeutic regimen, the patient showed three subcutaneous nodules under the left armpit and both sides of the cervical spine. Pathological examination of the nodules indicated DLBCL again. The patient was diagnosed with relapsed and refractory diffuse large B-cell lymphoma. We recommended CAR-T cell treatment. Before treatment, the patient’s T cell function and expression of immune detection points were tested. Expression of PD-1 was obviously increased (52.7%) on cluster of differentiation (CD)3+ T-cells; Zhang XJ analyzed and interpreted the data; Niu ZY contributed to the writing and Wang FX revised the manuscript.

A 61-year-old male presented with 15-d history of diarrhea and lower-limb edema. A large mass was detected in the pelvis, and pathology indicated non-Hodgkin diffuse large B-cell lymphoma. After three cycles of the R-CHOP chemotherapeutic regimen, the patient showed three subcutaneous nodules under the left armpit and both sides of the cervical spine. Pathological examination of the nodules indicated DLBCL again. The patient was diagnosed with relapsed and refractory diffuse large B-cell lymphoma. We recommended CAR-T cell treatment. Before treatment, the patient’s T cell function and expression of immune detection points were tested. Expression of PD-1 was obviously increased (52.7%) on cluster of differentiation (CD)3+ T-cells. The PD-1 inhibitor (3 mg/kg) was infused prior to lymphodepleting chemotherapy with fludarabine and cyclophosphamide. CAR-CD19 T cells of $3 \times 10^6$/kg and CAR-CD22 T cells $1 \times 10^6$/kg were infused, respectively. The therapeutic effect was significant, and the deoxyribonucleic acid copy numbers of CAR-CD19 T cells and CAR-CD22 T cells were stable. Presently, the patient has been disease-free for more than 12 mo.
CONCLUSION
This case suggests that the combination of PD-1 inhibitors and CAR-T cells improved therapeutic efficacy in B-cell lymphoma.

Key Words: Chimeric antigen receptor T cell; Programmed cell death protein 1 inhibitor; Relapsed/refractory non-Hodgkin lymphoma; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The mechanism of early loss of chimeric antigen receptor T (CAR-T) cells may be the depletion of activated T cells due to stimulation of the immune checkpoint pathway [such as programmed cell death protein-1 (PD-1)] of lymphoma cells. Immune checkpoints have a critical role in the immune system. This case suggests that PD-1 expression may affect the therapeutic effect of CAR-T cell therapy, and combination CAR-T cells and a PD-1 inhibitor may be a viable treatment option for relapsed and refractory non-Hodgkin lymphoma.

INTRODUCTION
With the development of new targeted drugs, the remission rate of non-Hodgkin lymphoma (NHL) has significantly improved, but some patients still experience relapse and refractory disease. In addition to targeted therapy, immunotherapy plays a leading role in the treatment of lymphoma. In particular, chimeric antigen receptor T (CART) cell immunotherapy has been beneficial for many refractory lymphoma patients. However, some B-cell lymphoma patients experience poor effects on this therapy. The efficacy of CAR-T cell therapy in patients with relapsed/refractory NHL has been less impressive compared to that in patients with acute lymphoid leukemia[1]. After 12 mo of CAR-T cell therapy, the relapse-free survival rate of patients is reduced to 60%, and the main cause of relapse is the early loss of CAR-T cells. The mechanism of loss may be the depletion of activated T cells due to stimulation of the immune checkpoint pathway [such as programmed cell death protein-1 (PD-1)] of lymphoma cells. Immune checkpoints have a critical role in the immune system. Based on the above theory, we boldly tried a combination of CAR-T cell therapy and a PD-1 inhibitor to treat a patient with relapsed and refractory NHL, which led to satisfactory results[2].

CASE PRESENTATION
Chief complaints
A 61-year-old male patient was admitted to the Gastrointestinal Surgery Department and subsequently transferred to the Hematology Department, Second Hospital of Hebei Medical University. He presented with diarrhea and edema of the lower limbs that had lasted for 15 d.

History of present illness
The patient’s symptoms of diarrhea and edema had started 15 d previously and had worsened over the last 2 d.

History of past illness
The patient had no previous medical history.
**Personal and family history**

The patient had no personal or family history.

**Physical examination**

The patient’s temperature was 36.6°C, heart rate was 88 bpm, respiratory rate was 18 breaths/min, blood pressure was 110/80 mmHg, and oxygen saturation in room air was 99%. Physical examination of hypogastria found a pelvis mass 15 cm in the maximum dimension. Our first clinical consideration was the possibility of sigmoid colorectal cancer.

**Laboratory examinations**

After admission, the blood work showed the following: white blood cells, $5.5 \times 10^9$/L; hemoglobin, 96 g/L; platelets, $358 \times 10^9$/L. His biochemical results were as follows: lactate dehydrogenase, 317 U/L; protein, 54.1 g/L; albumin, 29.5 g/L; β-2 microglobulin, 3.6 mg/L; creatinine, 118 μmol/L. A rectal biopsy of the large mass in the pelvis was performed, and the pathology results indicated non-Hodgkin diffuse large B-cell lymphoma [(DLBCL) non-germinatal center B-cell like]. The results of immunohistochemistry revealed the following: BCL-2 (–); BCL-6 (+); CD10 (+); CD20 (+); CD21 (–); CD3 (–); CD5 (scattered +); CD56 (–); chromogranin A (–); pan-cytokeratin (–); cyclinD1 (–); LCA (+); multiple myeloma 1 (–); paired box gene 5 (+); synaptophysin (–); vimentin (–); Ki-67 (> 80%); EBER (–).

**Imaging examinations**

Enhanced pelvic computed tomography (CT) examination revealed a large mass in the pelvis. Positron emission tomography-CT examination suggested that there was a high-metabolism mass in the pelvis; in addition, there were many high-metabolism shadows in the liver, pancreas, kidneys and bones. There were multiple high-metabolism nodules in the subcutaneous region, muscle, and right paracolon ditch. The results of flow cytometry showed that there was no lymphoma cell infiltration in the bone marrow.

**FINAL DIAGNOSIS**

The final diagnosis indicated non-Hodgkin DLBCL (non-germinatal center B-cell like). According to Ann Arbor staging classification, the lymphoma was categorized as stage IV.

**TREATMENT**

After two sessions of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) chemotherapy, the tumor disappeared completely. Two months later, the patient showed three subcutaneous nodules under the left armpit and both sides of the cervical spine. Pathological examination of the nodules also indicated DLBCL. The patient then underwent R-CHOP regimen chemotherapy again and received lenalidomide (25 mg/d, orally) for maintenance treatment.

One month later, the nodules were obviously enlarged. The patient was diagnosed with relapsed and refractory DLBCL. We recommended that he should receive anti-CD19 and anti-CD22 CAR-T cell treatment. Before treatment, the patient’s T cell function and expression of immune detection points were tested. The expression of PD-1 was obviously increased (52.7%) on the CD3+ T cells. Therefore, he was given a PD-1 inhibitor before CAR-T cell treatment. The PD-1 inhibitor carcixumab (3 mg/kg) was infused into the patient before fludarabine and cyclophosphamide pretreatment was administered. The numbers of CAR-CD19 T cells and CAR-CD22 T cells were $3 \times 10^6$/kg and $1 \times 10^6$/kg, respectively.

Eight day after CAR-T infusion, the lung CT showed that there were more nodules in both lungs. We considered the pulmonary nodules to be lymphoma. After the infusion of CAR-T cells for 10 d, the deoxyribonucleic acid (DNA) copy numbers of CAR-CD19 T cells and CAR-CD22 T cells were $7.98 \times 10^3$/μg and $3.07 \times 10^3$/μg, respectively. However, the peripheral blood cell counts decreased significantly, and many hemophagocytes were seen in the bone marrow. This systemic inflammatory response syndrome was related to CAR-T cell treatment, and the patient was treated...
with dexamethasone for 5 d.

OUTCOME AND FOLLOW-UP

On the 14th d after CAR-T cell treatment, the subcutaneous nodules began to shrink and were smaller. On the 19th d, PD-1 expression decreased to within the normal range (2.04%). On day 20 after combination therapy, the highest copy numbers of anti-CD19 and anti-CD22 CAR DNA detected were $8.13 \times 10^4$/µg and $2.26 \times 10^4$/µg, respectively. The changes in DNA copy numbers of CAR-CD19 T and CAR-CD22 T cells for 2 mo are shown in Figure 1. On the 21st d after initiating combination therapy, the results of lung CT showed that the multiple nodules in the two lungs had reduced in size (Figure 2A) and that the peripheral blood cell counts returned to normal levels. After 28 d of combination therapy, the skin nodules were reduced, and had disappeared by the 3rd mo (Figure 2B). In the 5th month, the DNA copy numbers of CAR-CD19 T cells and CAR-CD22 T cells were $1.82 \times 10^2$/µg and $1.92 \times 10^3$/µg, respectively. The patient’s positron emission tomography-CT results at this time showed complete metabolic remission of the lymphoma (Figure 2C). At present, the patient has been disease-free for more than 12 mo.

DISCUSSION

Emerging evidence has identified many types of inhibitory molecules, including immunosuppressive cells and cytokines, in the microenvironment of tumors; autoimmune inhibition may inhibit the activity of CAR-T cells and weaken its therapeutic effect[3]. Through the active interaction between checkpoint molecules and ligands, inhibitory signals can escape immune surveillance, leading to T cell failure and tumor tolerance[4]. The expression of PD-1 in CAR-T cells is significantly up-regulated, which reduces the level of anti-tumor immune response and allows tumor cells to escape the immune system[5]. In vitro experiments have shown that blocking the PD-1/PD-1 ligand (PD-L1) pathway not only increases the number of T cells but also enhances the anti-tumor effect of T cells by changing the tumor inhibitory microenvironment[6]. Previous studies have shown that PD-1 inhibitors can improve and prolong the therapeutic effect of CAR-T cells treatment[7]. Blocking the signal transduction between PD-L1 and PD-1 can improve the function of CAR-T cells and make their effect longer lasting[8]. CAR-T cell therapy combined with PD-1 inhibitors or cytokine inhibitors can improve the overall or local immune environment, which can significantly enhance the overall anti-tumor effect[9-11].

Clinical research has proven that combination CAR-T cell therapy and PD-1 checkpoint blocker is a very effective treatment for solid tumors, and this combination has yielded good results in the treatment of hematologic tumors[12,13]. Another way to combine CAR-T cell therapy with an immunosuppressant is genetic engineering. T cells expressing the single-chain variable fragment of PD-1 antibody can block the interaction between immune cell PD-1 and tumor cell PD-L1, thus negating the immunosuppression[14]. Therefore, using genetic engineering to knock out the PD-1 gene or "graft" PD-1 antibody into CAR-T cells is one direction for new research in CAR-T cell therapies[10].

Our research has confirmed once again that PD-1 blockade plays a key role in the regulation of T cell-mediated anti-tumor therapy. The combination not only improved the therapeutic efficacy in B-cell lymphoma but also provided a novel treatment option for relapsed/refractory instances of the disease. In addition to PD-1, there are other immune checkpoints on lymphoma cells. Whether blocking them can also improve the efficacy of CAR-T cell therapy remains to be determined.

CONCLUSION

In summary, the effect of the standard treatment regimen in this patient with relapsed/refractory B-cell lymphoma was poor. Before CART cell therapy, we detected a high expression of PD-1 in the T cells of the patient. We predicted that PD-1 expression may affect the therapeutic effect of CAR-T cell therapy and chose to combine it with a PD-1 inhibitor. This method can solve the problems of poor efficacy of CAR-T cells and the short-term efficacy of PD-1 inhibitors as well as improve the
Figure 1 DNA variation trend of CD19-CAR-T cell and CD22-CAR-T cell. Copy number of CD19-CAR-T cells and CD22-CAR-T cells DNA per μg genome in peripheral blood of the lymphoma patient at different times. CAR: Chimeric antigen receptor; DNA: Deoxyribonucleic acid.

Figure 2 Changes in lung, subcutaneous mass, and abdominal mass before and after chimeric antigen receptor T cell therapy. A: The patient developed multiple pulmonary nodules after disease progression detected by computed tomography. After treatment with chimeric antigen receptor T cell (CAR-T) and programmed cell death protein-1 inhibitor for 21 days, the absorption of pulmonary nodules decreased significantly; B: Changes in the subcutaneous mass before and after CAR-T cell therapy. The comparison of local mass size before and after CAR-T cell treatment in the 1st mo and 3rd mo; and C: Changes in the abdominal mass detected by positron emission tomography-computed tomography before and after CAR-T cell therapy. In early diagnosis of the disease, the maximum standardized uptake values were 22.40 and 15.60 in the abdomen and pelvis, respectively. 5 mo after the combination treatment, the maximum standardized uptake values in the abdomen and pelvis were 3.80 and 3.30, respectively.

therapeutic effect of CAR-T cell therapy. The combination not only improved the therapeutic efficacy in B-cell lymphoma but also provided the basis for a new treatment for relapsed/refractory instances of the disease.

REFERENCES

1. Zhang R, Deng Q, Jiang YY, Zhu HB, Wang J, Zhao MF. Effect and changes in PD1 expression of CD19 CART cells from T cells highly expressing PD1 combined with reduceddose PD1 inhibitor.
Niu ZY et al. Treatment of relapsed/refractory NHL

Oncol Rep 2019; 41: 3455-3463 [PMID: 30942469 DOI: 10.3892/or.2019.7096]

2 Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. *Clin Immunol* 2020; 214: 108382 [PMID: 32169439 DOI: 10.1016/j.clim.2020.108382]

3 Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. *Cancer Immunol Res* 2019; 7: 363-375 [PMID: 30651290 DOI: 10.1158/2326-6066.CIR-18-0572]

4 Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. *Mol Ther* 2016; 24: 1135-1149 [PMID: 27019997 DOI: 10.1038/mt.2016.63]

5 McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. *Biomed Pharmacother* 2020; 121: 109625 [PMID: 3173578 DOI: 10.1016/j.biopha.2019.109625]

6 Shi X, Zhang D, Li F, Zhang W, Wang S, Xuan Y, Ping Y, Zhang Y. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. *J Hematol Oncol* 2019; 12: 127 [PMID: 31783892 DOI: 10.1186/s13045-019-0831-5]

7 Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. *J Hematol Oncol* 2019; 12: 59 [PMID: 31186046 DOI: 10.1186/s13045-019-0746-1]

8 Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest* 2016; 126: 3130-3144 [PMID: 27454297 DOI: 10.1172/JCI83092]

9 Simon B, Harrer DC, Schuler-Thurner B, Schaft N, Schuler G, Dörrie J, Uslu U. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. *Exp Dermatol* 2018; 27: 769-778 [PMID: 29704887 DOI: 10.1111/exd.13678]

10 Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. *Cancer Immunol Immunother* 2019; 68: 365-377 [PMID: 30523370 DOI: 10.1007/s00262-018-2281-2]

11 Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. *Mol Ther* 2017; 25: 2214-2224 [PMID: 28602436 DOI: 10.1016/j.ymthe.2017.05.012]

12 Chen N, Morello A, Tano Z, Adusumilli PS. CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. *Oncosimmunology* 2017; 6: e1273302 [PMID: 28348886 DOI: 10.1080/2162402X.2016.1273302]

13 Wang J, Deng Q, Jiang YY, Zhang R, Zhu HB, Meng JX, Li YM. CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report. *Oncol Lett* 2019; 18: 4415-4420 [PMID: 31611950 DOI: 10.3892/ol.2019.10783]

14 Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. *Nat Biotechnol* 2018; 36: 847-856 [PMID: 30102295 DOI: 10.1038/nbt.4195]
